Cosmo Pharmaceuticals N.V./Fr. COPN
08:00
10:05
12:10
14:15
16:20
1D1W1MYTD1Y5YMAX
About Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company based in Lainate, Italy, focusing on the development and manufacturing of products for specific gastrointestinal diseases. The company's core business involves oral therapies, particularly for conditions such as inflammatory bowel disease and colon cancer. Notable products include Lialda/Mezavant, a treatment for ulcerative colitis, and Eleview, a medical device used in endoscopic procedures. Cosmo Pharmaceuticals leverages proprietary drug delivery technologies to enhance treatment efficacy and patient compliance. While headquartered in Italy, it operates primarily within the European market and maintains a strategic partnership network to expand its global reach.
Ticker
Fr. COPN
Sector
Primary listing
XSWX
Employees
332
Headquarters
Dublin, Ireland
Website
COPN Metrics
BasicAdvanced
CHF 1.8B
34.31
CHF 3.36
1.29
CHF 1.92
1.67%
Price and volume
Market cap
CHF 1.8B
Beta
1.29
52-week high
CHF 129.40
52-week low
CHF 41.60
Average daily volume
79K
Dividend rate
CHF 1.92
Financial strength
Current ratio
3.843
Quick ratio
3.589
Long term debt to equity
0.416
Total debt to equity
0.578
Dividend payout ratio (TTM)
94.36%
Interest coverage (TTM)
763.58%
Profitability
EBITDA (TTM)
73.634
Gross margin (TTM)
73.79%
Net profit margin (TTM)
32.91%
Operating margin (TTM)
37.70%
Effective tax rate (TTM)
16.87%
Revenue per employee (TTM)
CHF 503,370
Management effectiveness
Return on assets (TTM)
6.88%
Return on equity (TTM)
12.34%
Valuation
Price to earnings (TTM)
34.309
Price to revenue (TTM)
11.25
Price to book
4
Price to tangible book (TTM)
17.17
Price to free cash flow (TTM)
30.714
Free cash flow yield (TTM)
3.26%
Free cash flow per share (TTM)
3.751
Dividend yield (TTM)
1.67%
Forward dividend yield
1.67%
Growth
Revenue change (TTM)
-1.66%
Earnings per share change (TTM)
0.09%
3-year revenue growth (CAGR)
32.61%
10-year revenue growth (CAGR)
12.03%
3-year earnings per share growth (CAGR)
23.18%
10-year earnings per share growth (CAGR)
-13.78%
3-year dividend per share growth (CAGR)
29.22%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cosmo Pharmaceuticals N.V. stock?
Cosmo Pharmaceuticals N.V. (COPN) has a market cap of Fr.1.8B as of February 12, 2026.
What is the P/E ratio for Cosmo Pharmaceuticals N.V. stock?
The price to earnings (P/E) ratio for Cosmo Pharmaceuticals N.V. (COPN) stock is 34.31 as of February 12, 2026.
Does Cosmo Pharmaceuticals N.V. stock pay dividends?
Yes, the Cosmo Pharmaceuticals N.V. (COPN) stock pays dividends to shareholders. As of February 12, 2026, the dividend rate is Fr.1.91967 and the yield is 1.67%. Cosmo Pharmaceuticals N.V. has a payout ratio of 94.36% on a trailing twelve-month basis.
When is the next Cosmo Pharmaceuticals N.V. dividend payment date?
The next Cosmo Pharmaceuticals N.V. (COPN) dividend payment date is unconfirmed.
What is the beta indicator for Cosmo Pharmaceuticals N.V.?
Cosmo Pharmaceuticals N.V. (COPN) has a beta rating of 1.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.